Literature DB >> 31358593

Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats.

Melissa J Karau1, Suzannah M Schmidt-Malan1, Qun Yan2, Kerryl E Greenwood-Quaintance1, Jayawant Mandrekar3, Dario Lehoux4, Raymond Schuch4, Cara Cassino4, Robin Patel5,6.   

Abstract

Bacteriophage-derived lysins are being developed as anti-infective agents. In an acute osteomyelitis methicillin-resistant Staphylococcus aureus (MRSA) model, rats receiving no treatment or treatment with daptomycin, exebacase (CF-301), or daptomycin plus exebacase had means of 5.13, 4.09, 4.65, and 3.57 log10 CFU/gram of bone, respectively. All treated animals had fewer bacteria than did untreated animals (P ≤ 0.0001), with daptomycin plus exebacase being more active than daptomycin (P = 0.0042) or exebacase (P < 0.001) alone.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  CF-301; daptomycin; exebacase; methicillin-resistant Staphylococcus aureuszzm321990; osteomyelitis

Year:  2019        PMID： 31358593      PMCID： PMC6761499          DOI： 10.1128/AAC.01235-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis.

Authors:  Mark S Rouse; Kerryl E Piper; Melissa Jacobson; David J Jacofsky; James M Steckelberg; Robin Patel
Journal:  J Antimicrob Chemother       Date:  2005-12-16       Impact factor: 5.790

2.  In vitro activity of tedizolid against staphylococci isolated from prosthetic joint infections.

Authors:  Suzannah M Schmidt-Malan; Kerryl E Greenwood Quaintance; Melissa J Karau; Robin Patel
Journal:  Diagn Microbiol Infect Dis       Date:  2016-01-12       Impact factor: 2.803

3.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

4.  Comparison of Methicillin-resistant Versus Susceptible Staphylococcus aureus Pediatric Osteomyelitis.

Authors:  William T Davis; Shawn R Gilbert
Journal:  J Pediatr Orthop       Date:  2018 May/Jun       Impact factor: 2.324

5.  Penetration of daptomycin into bone and synovial fluid in joint replacement.

Authors:  D Montange; F Berthier; G Leclerc; A Serre; L Jeunet; M Berard; P Muret; L Vettoretti; J Leroy; B Hoen; C Chirouze
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

6.  Systemic antimicrobial therapy in osteomyelitis.

Authors:  Henry S Fraimow
Journal:  Semin Plast Surg       Date:  2009-05       Impact factor: 2.314

7.  Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent.

Authors:  Raymond Schuch; Babar K Khan; Assaf Raz; Jimmy A Rotolo; Michael Wittekind
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

8.  Novel Bone-Targeting Agent for Enhanced Delivery of Vancomycin to Bone.

Authors:  Zaineb A F Albayati; Manjula Sunkara; Suzannah M Schmidt-Malan; Melissa J Karau; Andrew J Morris; James M Steckelberg; Robin Patel; Philip J Breen; Mark S Smeltzer; K Grant Taylor; Kevyn E Merten; William M Pierce; Peter A Crooks
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

9.  Treatment of Methicillin-resistant Staphylococcus aureus experimental Osteomyelitis with bone-targeted Vancomycin.

Authors:  Melissa J Karau; Suzannah M Schmidt-Malan; Kerryl E Greenwood-Quaintance; Jayawant Mandrekar; Jian Cai; William M Pierce; Kevyn Merten; Robin Patel
Journal:  Springerplus       Date:  2013-07-18

10.  Determining bacteriophage endopeptidase activity using either fluorophore-quencher labeled peptides combined with liquid chromatography-mass spectrometry (LC-MS) or Förster resonance energy transfer (FRET) assays.

Authors:  Rolf Lood; Henrik Molina; Vincent A Fischetti
Journal:  PLoS One       Date:  2017-03-15       Impact factor: 3.240
View more
  10 in total

Review 1.  Biological challenges of phage therapy and proposed solutions: a literature review.

Authors:  Katherine M Caflisch; Gina A Suh; Robin Patel
Journal:  Expert Rev Anti Infect Ther       Date:  2019-12-02       Impact factor: 5.091

2.  Lysins - a new armamentarium for the treatment of bone and joint infections?

Authors:  Parham Sendi; Tristan Ferry
Journal:  J Bone Jt Infect       Date:  2022-09-06

3.  Arthroscopic "Debridement and Implant Retention" With Local Administration of Exebacase (Lysin CF-301) Followed by Suppressive Tedizolid as Salvage Therapy in Elderly Patients for Relapsing Multidrug-Resistant S. epidermidis Prosthetic Knee Infection.

Authors:  Tristan Ferry; Cécile Batailler; Aubin Souche; Cara Cassino; Christian Chidiac; Thomas Perpoint; Claire le Corvaisier; Jérôme Josse; Romain Gaillard; Julien Roger; Camille Kolenda; Sébastien Lustig; Frédéric Laurent
Journal:  Front Med (Lausanne)       Date:  2021-05-14

Review 4.  Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection.

Authors:  Tristan Ferry; Camille Kolenda; Thomas Briot; Aubin Souche; Sébastien Lustig; Jérôme Josse; Cécile Batailler; Fabrice Pirot; Mathieu Medina; Gilles Leboucher; Frédéric Laurent
Journal:  Viruses       Date:  2021-12-02       Impact factor: 5.048

Review 5.  Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance.

Authors:  Raymond Schuch; Cara Cassino; Xavier Vila-Farres
Journal:  Front Microbiol       Date:  2022-03-03       Impact factor: 5.640

Review 6.  Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections.

Authors:  Matthew W McCarthy
Journal:  Drugs R D       Date:  2022-02-17

7.  Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis.

Authors:  Melissa Karau; Suzannah Schmidt-Malan; Jay Mandrekar; Dario Lehoux; Raymond Schuch; Cara Cassino; Robin Patel
Journal:  J Bone Jt Infect       Date:  2022-07-27

8.  Activity of Exebacase (CF-301) against Biofilms Formed by Staphylococcus epidermidis Strains Isolated from Prosthetic Joint Infections.

Authors:  Aubin Souche; Camille Kolenda; Jordan Teoli; Raymond Schuch; Tristan Ferry; Frédéric Laurent; Jérôme Josse
Journal:  Antimicrob Agents Chemother       Date:  2022-07-11       Impact factor: 5.938

9.  Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis.

Authors:  Melissa J Karau; Suzannah M Schmidt-Malan; Scott A Cunningham; Jayawant N Mandrekar; Bobbi S Pritt; Tiffany R Keepers; Alisa W Serio; Surya Chitra; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2021-11-01       Impact factor: 5.191

Review 10.  Bacteriophage Proteome: Insights and Potentials of an Alternate to Antibiotics.

Authors:  Bilal Aslam; Muhammad Imran Arshad; Muhammad Aamir Aslam; Saima Muzammil; Abu Baker Siddique; Nafeesa Yasmeen; Mohsin Khurshid; Maria Rasool; Moeed Ahmad; Muhammad Hidayat Rasool; Mohammad Fahim; Riaz Hussain; Xueshan Xia; Zulqarnain Baloch
Journal:  Infect Dis Ther       Date:  2021-06-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.